!

virus expected to add pressure on hospitals in many EU/EEA countries this season.

Thirteen EU/EEA Member States have reported a rise in RSV cases between October and 14 November 2022.

Full press release: ecdc.europa.eu/en/news-events/

🐦🔗: nitter.eu/ECDC_EU/status/15954

Follow

Respiratory syncytial virus () is a seasonal virus that recurs throughout the year in Europe with peaks mainly during the autumn, winter, and spring months (October to April), and is a leading cause of acute lower respiratory tract infections in infants and young children.

🐦🔗: nitter.eu/ECDC_EU/status/15954

· · mirror-bot · 1 · 0 · 1

Worldwide, the virus is estimated to cause 33 million cases and 66 000 to 199 000 deaths of children below five years every year.

In the EU, Norway and the United Kingdom, RSV causes an average of 213 000 annual hospitalisations in children under five years.

🐦🔗: nitter.eu/ECDC_EU/status/15954

can also cause serious complications and deaths among adults, particularly those aged 65 years and older.

Hospitalisations for adults in the EU, Norway and the United Kingdom are on average 158 000 per year.

Read more: ecdc.europa.eu/en/news-events/

🐦🔗: nitter.eu/ECDC_EU/status/15954

Nearly all children are infected by by the age of two years, and reinfections are common.

Although infection is nearly unavoidable most children, special efforts should nevertheless be made to protect preterm babies and infants younger than six months old.

🐦🔗: nitter.eu/ECDC_EU/status/15954

In addition, toddlers who have not encountered during the pandemic would be at an increased risk of infection.

Therapeutics against severe RSV infection have been approved, and researchers are in the process of developing vaccines.

🐦🔗: nitter.eu/ECDC_EU/status/15954

Sign in to participate in the conversation
Mastodon

A Mastodon forum for the discussion of European Union matters. Not run by the EU. Powered by PleromaBot, Nitter and PrivacyDev.net.